[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novavax Inc (NVAX)

Novavax Inc (NVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes

One of the remarkable turnaround stories during the COVID-19 pandemic, biotechnology specialist Novavax (NVAX) has struggled to maintain viability since its glory days. However, NVAX stock happens to be on a roll this year, thanks to key licensing agreements and most recently an unexpectedly positive first-quarter earnings report.

Late last week, Novavax posted a loss of 6 cents per share, which was a far superior result than the expected loss of 25 cents. Further, revenue for the period clocked in at $139.5 million, demolishing the consensus view of $69.5 million. Without getting too carried away, the sales tally represented a...

Fundamentals

See More
  • Market Capitalization, $K 1,662,468
  • Shares Outstanding, K 164,438
  • Annual Sales, $ 1,123 M
  • Annual Income, $ 440,300 K
  • EBIT $ 453 M
  • EBITDA $ 480 M
  • 60-Month Beta 2.37
  • Price/Sales 1.35
  • Price/Cash Flow 2.63
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 84.88% (+3.58%)
  • Historical Volatility 64.56%
  • IV Percentile 63%
  • IV Rank 15.73%
  • IV High 257.13% on 01/28/26
  • IV Low 52.73% on 06/30/25
  • Expected Move (DTE 4) 0.82 (8.59%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 33,256
  • Volume Avg (30-Day) 16,196
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 254,994
  • Open Int (30-Day) 220,889
  • Expected Range 8.68 to 10.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 3
  • High Estimate $-0.29
  • Low Estimate $-0.42
  • Prior Year $0.62
  • Growth Rate Est. (year over year) -158.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.71 +23.22%
on 04/29/26
10.75 -11.63%
on 05/08/26
+1.38 (+17.00%)
since 04/10/26
3-Month
7.57 +25.58%
on 04/02/26
11.97 -20.63%
on 02/26/26
+0.53 (+5.91%)
since 02/11/26
52-Week
5.86 +61.98%
on 05/14/25
11.97 -20.63%
on 02/26/26
+3.53 (+59.00%)
since 05/09/25

Most Recent Stories

More News
Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes

Although a better-than-expected Q1 earnings print has NVAX stock skyrocketing recently, there’s a high risk in chasing this biotech play.

NVAX : 9.50 (-6.03%)
Why Novavax (NVAX) Stock Is Trading Up Today

Why Novavax (NVAX) Stock Is Trading Up Today

NVAX : 9.50 (-6.03%)
Novavax to Participate in BofA Securities 2026 Health Care Conference

GAITHERSBURG, Md. , May 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2026 Health Care Conference.

NVAX : 9.50 (-6.03%)
Novavax: Q1 Earnings Snapshot

Novavax: Q1 Earnings Snapshot

NVAX : 9.50 (-6.03%)
Novavax (NASDAQ:NVAX) Surprises With Strong Q1 CY2026, Stock Soars

Novavax (NASDAQ:NVAX) Surprises With Strong Q1 CY2026, Stock Soars

NVAX : 9.50 (-6.03%)
Novavax Reports First Quarter 2026 Financial Results and Operational Highlights

GAITHERSBURG, Md. , May 6, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2026.

NVAX : 9.50 (-6.03%)
Has Novavax Already Reported Everything That Mattered About This Quarter?

Barchart Research What to Expect from NVAX Earnings NVAX Generated May 5, 2026 Current Price $8.11 EPS Estimate $$-0.25 Consensus Rating Moderate Buy Average Move 20.08% Has Novavax Already Reported Everything...

NVAX : 9.50 (-6.03%)
Novavax (NVAX) Q1 Earnings Report Preview: What To Look For

Novavax (NVAX) Q1 Earnings Report Preview: What To Look For

NVAX : 9.50 (-6.03%)
Novavax to Report First Quarter 2026 Financial Results on May 6, 2026

GAITHERSBURG, Md. , April 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern...

NVAX : 9.50 (-6.03%)
1 Cash-Heavy Stock to Target This Week and 2 We Ignore

1 Cash-Heavy Stock to Target This Week and 2 We Ignore

POWL : 322.05 (+4.09%)
TXG : 20.50 (-5.09%)
NVAX : 9.50 (-6.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple...

See More

Key Turning Points

3rd Resistance Point 11.83
2nd Resistance Point 11.29
1st Resistance Point 10.39
Last Price 9.50
1st Support Level 8.95
2nd Support Level 8.41
3rd Support Level 7.51

See More

52-Week High 11.97
Fibonacci 61.8% 9.64
Last Price 9.50
Fibonacci 50% 8.92
Fibonacci 38.2% 8.20
52-Week Low 5.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.